"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approves olaparib tablets (Lynparza) for the treatment of patients with deleterious or suspected deleterious gBRCAm breast cancer

FDA Approves olaparib tablets (Lynparza) for the treatment of patients with deleterious or suspected deleterious gBRCAm breast cancer

12 Jan 2018 1:20 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approval to olaparib tablets (Lynparza; AstraZeneca) a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software